8:25 am Chair’s Opening Remarks
8:30 am Panel Discussion: How Can Investors & Companies Work Together to Save GBM Funding?
Synopsis
- Addressing how to attract investment for novel therapies which are not yet clinically proven
- Understanding how to gain support for novel strategies, including combination therapy trials
- Comparing the two main sources of funding- public vs private funding
Speakers To Be Announced
9:10 am
Learning First Hand Advice from Experts Exploring the Current Landscape of GBM Precision Therapeutics
9:45 am Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden
Synopsis
- Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines
- Lessons learned from a single-arm phase 2 trial in primary GBM
- Randomized, blinded phase 3 trial in primary GBM
10:15 am Morning Break & Networking
11:00 am Development of Imvax’s IGV-001 for the Treatment of Newly Diagnosed Glioblastoma Utilizes a Personalized Tumor-Derived Immunotherapy Platform Exploiting the Full Antigenic Signature of GBM
Synopsis
- IGV-001, an autologous cell Immunotherapy with antisense oligonucleotide (IMV-001) targeting IGF1R, is a biologic-device combination product developed from Imvax’s proprietary platform, GoldspireTM
- Imvax’s GBM program builds on published Phase 1b data to leverage this cell-based autologous immunotherapy to combat the immunosuppressive GBM TME
- A randomized, multicenter, double-blind, placebo-controlled, Phase 2b study assessing the safety and efficacy of IGV-001 in newly diagnosed patients with glioblastoma enrolled the first patient in March 2023
- The Phase 2b trial will enroll up to 93 participants in a 2:1 randomization across approximately 25 sites in the U.S. and is on schedule to complete enrollment in the first half of 2024
- The primary endpoint of the study is median progression-free survival (PFS) and key secondary endpoints include overall survival and safety, with PFS data expected to be available in mid-2025
11:30 am Biopharma Insights Within the GBM Space – GBM Precision Discovery Strategy at Bristol-Myers Squibb
Synopsis
- Overview of the ongoing R&D work in GBM at Bristol-Myers Squibb
- Leveraging clinical datasets to understand the disease
- Implementing a precision discovery strategy to succeed
12:00 pm Targeting MAPK Signalling Pathways to Stop GBM Tumor Cell Proliferation
Synopsis
- Introducing a new generation of brain penetrant BRAF inhibitors for GBM
- ABM-1310 for BRAF v600-mutant GBM tumors- Phase I study
- Clinical evidence of ABM-1310 in high grade gliomas including GBM
12:30 pm Lunch
1:25 pm
Exploring the Current Landscape of GBM Precision Therapeutics – Hear First Hand Advice from Experts
1:30 pm Leveraging Immune Checkpoint Inhibitors to Target Multiple Tumor Microenvironment Cell Population
Synopsis
- Novel biological activity stimulates thrombospondin-1 expression to target myeloid and inflammatory cells in the TME via CD36 and CD47
- Understand the influence of the TME and peripheral immune cells in GBM IO treatment
- Discuss promising biomarkers for responses to immune checkpoint inhibitors
2:00 pm Leveraging Engineered Gamma-Delta T Cells for Enhanced Tumor Cell Destruction in GBM
Synopsis
- Overcoming challenges of antigen selection with engineered T-cells for GBM tumor destruction
- Using gamma-delta T cells to combine an innate and adaptive immune response in GBM
- Determining the best combinatorial approach for cell therapy in solid tumors
2:30 pm Harnessing Oncolytic Viruses to Surpass the ‘Cold’ Tumor Microenvironment
Synopsis
- Design of novel oncolytic viruses to inhibit the immunosuppressive microenvironment, expose multiple tumor antigens and selectively kill cancer cells for an individualized immune response
- Evaluate viral immunotherapy showing promise in treatment resistant high-grade glioma
- Review clinical and biomarker data from a phase 1 study of CAN-3110 in recurrent high grade gliomaÂ
3:00 pm Afternoon Break
3:05 pm
Exploring the Current Landscape of GBM Precision Therapeutics – Hear First Hand Advice from Experts
3:30 pm Targeted DNA Modification: A New Paradigm to Exploit DDR Defects in Glioma and Beyond…
Synopsis
- Discuss Modifi Bio’s development candidate which selectively targets MGMT-deficient cancers
- Review data suggesting efficacy of these molecules across a range of brain tumor models, as a monotherapy and in combination with other agents
- Highlights of Modifi’s biomarker strategy to enrich for MGMT- gliomas with acquired MMR mutations in a phase 0/I trial
4:00 pm EGFRvIII-Targeted Alpha Therapy for Precision Cancer Cell Destruction in GBM
Synopsis
- What is targeted alpha therapy (TAT) and theranostics?
- Advantages of TAT for treatment of GBM
- Preclinical evaluation of an EGFRvIII-targeted alpha therapy in PDX models with varying degrees of BBB permeability
4:30 pm Reinventing Radioligand Therapy for Targeted Tumor Cell Destruction
Synopsis
- The pipeline of targeted radiotherapy approaches for GBM
- Novel methods of overcoming existing barriers to targeted radiotherapy
- An update on present and upcoming Novartis research in GBM
5:00 pm Delaying Disease Progression & Boosting Therapeutic Efficacy By Targeting the DNA Damage Response
Synopsis
- Reviewing the landscape of DDR targeted approaches
- Targeting DDR mechanisms to enhance efficacy of other treatments
- Tackling the incorporation of DDR agents from a regulatory standpoint